• Pigmented lesion assay (PLA) is used to non-invasively detect the presence of 3 genes associated with melanoma (LINC, PRAME, TERT).
  • For melanomas, prognostic gene expressing profile testing is not currently recommended for clinical use per the Melanoma Prevention Working Group.
  • Immune-related cutaneous adverse events occur in 70-90% of patients treated with immune checkpoint inhibitors. Dupilumab is an effective treatment option.